DAEWOONG CO.,LTD
003090 | KO
Overview
Corporate Details
- ISIN(s):
- KR7003090008
- LEI:
- Country:
- South Korea
- Address:
- 경기 성남시 중원구 상대원동 223-23, 성남시
- Website:
- https://www.daewoong.co.kr
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
No description available.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
You have of free filing views remaining.
Upgrade for unlimited access.
Bulk Actions:
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2025-09-15 00:00 |
Regulatory Filings
투자판단관련주요경영사항(자회사의 주요경영사항)
|
Korean | 14.9 KB | ||
| 2025-09-05 00:00 |
Regulatory Filings
투자판단관련주요경영사항(자회사의 주요경영사항)
|
Korean | 9.0 KB | ||
| 2025-08-14 00:00 |
Annual Report
[기재정정]사업보고서 (2024.12)
|
Korean | 3.7 MB | ||
| 2025-08-14 00:00 |
Interim / Quarterly Report
반기보고서 (2025.06)
|
Korean | 4.0 MB | ||
| 2025-07-30 00:00 |
Regulatory Filings
투자판단관련주요경영사항(자회사의 주요경영사항)
|
Korean | 9.5 KB | ||
| 2025-06-02 00:00 |
Governance Information
기업지배구조보고서공시
|
Korean | 708.5 KB | ||
| 2025-05-16 00:00 |
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
|
Korean | 25.7 KB | ||
| 2025-05-16 00:00 |
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
|
Korean | 162.0 KB | ||
| 2025-05-16 00:00 |
Major Shareholding Notification
최대주주등소유주식변동신고서
|
Korean | 58.0 KB | ||
| 2025-05-15 00:00 |
Major Shareholding Notification
[기재정정]최대주주등소유주식변동신고서
|
Korean | 54.8 KB | ||
| 2025-05-15 00:00 |
Quarterly Report
분기보고서 (2025.03)
|
Korean | 2.1 MB | ||
| 2025-05-14 00:00 |
Major Shareholding Notification
[기재정정]최대주주등소유주식변동신고서
|
Korean | 60.7 KB | ||
| 2025-04-16 00:00 |
Capital/Financing Update
단기차입금증가결정(자회사의 주요경영사항)
|
Korean | 11.5 KB | ||
| 2025-04-02 00:00 |
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
|
Korean | 24.0 KB | ||
| 2025-04-01 00:00 |
Major Shareholding Notification
주식등의대량보유상황보고서(약식)
|
Korean | 62.4 KB |
Automate Your Workflow. Get a real-time feed of all DAEWOONG CO.,LTD filings delivered via API.
Market Data
Market Data Not Available
Last Price
Change / %
Market Cap
N/A
Volume
Day High
Day Low
52W High
52W Low
Financials & KPIs
No data available
Unlock Full Financials for DAEWOONG CO.,LTD
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for DAEWOONG CO.,LTD via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
Company
Country
Ticker
View
Develops targeted oral therapies for a range of gastrointestinal (GI) diseases.
United States of America
ENTO
United States of America
ENTO
Developing intracellular therapeutics for rare neuromuscular diseases via its EEV™ platform.
United States of America
TRDA
United States of America
TRDA
South Korea
183490
Develops medical devices with patented enzyme technology to treat upper respiratory infections.
Sweden
ENZY
Sweden
ENZY
Develops ingestible therapeutic devices for weight management and targeted drug delivery.
Israel
EPIT
Israel
EPIT
Develops and sells cost-efficient niche generic medicines for the Nordic healthcare market.
Sweden
EQL
Sweden
EQL
Clinical-stage oncology company developing therapies targeting the RAS/MAPK pathway in cancer.
United States of America
ERAS
United States of America
ERAS
Developing targeted, off-the-shelf cell therapies for cancer and autoimmune diseases.
United States of America
ERNA
United States of America
ERNA
Developing phage therapies to combat antibiotic-resistant bacterial infections.
France
ERYP
France
ERYP
Develops oral ACLY inhibitors to lower high LDL-C and cardiovascular risk.
United States of America
ESPR
United States of America
ESPR